Reddress Ltd v. Mimix Awc Corp

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: RedDress Ltd. (Israel)
  • Defendant: mimiX AWC Corp. (Delaware) and mimiX Biotherapeutics, S.A. (Switzerland)
  • Plaintiff's Counsel: McCARTER & ENGLISH, LLP
• Case Identification: 1:26-cv-00694, D. Del., 06/12/2026
• Venue Allegations: Venue is alleged to be proper as to Defendant mimiX AWC Corp. because it is a Delaware corporation subject to personal jurisdiction in the district. Venue is alleged as proper for mimiX Biotherapeutics, S.A. on the basis that it is a Swiss corporation subject to personal jurisdiction in the district.
• Core Dispute: Plaintiff alleges that Defendants' FastSkin® Patch, a kit for creating wound dressings from a patient's own blood, infringes two patents covering methods and systems for point-of-care preparation of biological wound dressings.
• Technical Context: The technology involves creating an autologous wound dressing by clotting a patient's whole blood outside the body, seeking to leverage the full biological spectrum of healing factors naturally present in blood.
• Key Procedural History: The complaint alleges that Defendant mimiX Biotherapeutics, S.A. filed a 510(k) premarket notification with the FDA to market the accused FastSkin® Patch, identifying Plaintiff's own ActiGraft® product as the predicate device. The complaint also alleges that Plaintiff provided Defendants with pre-suit notice of infringement through letters and an in-person meeting between the parties' executives, where one of the named inventors explained the alleged infringement.

Case Timeline

Date	Event
2009-01-27	Priority Date for '979 and '142 Patents
2015-11-10	'142 Patent Issued
2018-10-30	'979 Patent Issued
2026-04-09	Meeting between Plaintiff and Defendant executives
2026-06-12	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,111,979 - Wound Dressings, Methods and Apparatus for Making Same and Storage and Use Thereof, Issued October 30, 2018

The Invention Explained

• Problem Addressed: The patent addresses the limitations of prior art wound care, which relied on fractionated blood components (e.g., platelet-rich plasma), recombinant growth factors, or synthetic sealants Compl. ¶3 These approaches failed to utilize the comprehensive healing properties found in unfractionated whole blood for treating chronic wounds like ulcers and burns '979 Patent, col. 1:24-57
• The Patented Solution: The invention provides a method for creating a biological wound dressing by withdrawing a patient's own venous blood, mixing it with a coagulation initiator, and allowing it to clot ex vivo (outside the body) to form a sterile, solid clot '979 Patent, abstract '979 Patent, claim 1 This clotted-blood sheet, which may be combined with a support matrix, is then applied to the wound, effectively creating an artificial scab that leverages the body's complete natural healing apparatus '979 Patent, col. 5:11-19
• Technical Importance: The use of autologous, unfractionated whole blood provides a comprehensive biological dressing while greatly reducing the potential for an adverse immune response that could arise from using donor blood or synthetic products Compl. ¶4

Key Claims at a Glance

• The complaint asserts independent claims 1 and 5 Compl. ¶49
• Independent Claim 1 recites a method with the essential steps of: (1) withdrawing a volume of venous blood; (2) mixing it with a coagulation initiator; (3) allowing it to clot at a location physically separated from the wound; (4) combining the resulting whole-blood clot with a support matrix to form a sterile wound dressing; and (5) applying the dressing to the wound and leaving it in place for at least two days Compl. ¶28
• Independent Claim 5 recites a similar method with a different sequence of steps: (1) withdrawing venous blood; (2) mixing with a coagulation initiator; (3) introducing the blood to a receptacle to clot; (4) transferring the clot onto the wound; (5) applying a support matrix onto the clot when on said wound; and (6) leaving the dressing in place for at least two days Compl. p. 8
• The complaint also asserts dependent claims 2, 4, and 7 and reserves the right to assert others Compl. ¶49

U.S. Patent No. 9,180,142 - Wound Dressings, Methods and Apparatus for Making Same and Storage and Use Thereof, Issued November 10, 2015

The Invention Explained

• Problem Addressed: The '142 Patent, which is a parent to the '979 Patent, addresses the same technical problem: the need for a comprehensive biological wound dressing for chronic wounds that overcomes the limitations of using fractionated or synthetic blood products '142 Patent, col. 1:21-55
• The Patented Solution: The patent describes a method for creating a wound dressing that involves first mixing withdrawn sterile whole blood with an anticoagulant, then mixing that combination with a coagulation initiator to override the anticoagulant and trigger clotting '142 Patent, claim 1 A key aspect of the claimed method is spreading the now-clotting blood onto a support matrix at a location separate from the wound and allowing it to clot on the matrix to form the final dressing ('142 Patent, col. 4:48-64; '142 Patent, claim 1(d)-(e)).
• Technical Importance: This method provides a controllable, point-of-care process to create a fully autologous biological dressing that mimics a natural scab for non-bleeding wounds like burns and ulcers Compl. ¶4

Key Claims at a Glance

• The complaint asserts independent claims 1 and 9 Compl. ¶61
• Independent Claim 1 recites a method with the essential steps of: (a) obtaining sterile whole blood; (b) mixing it with an anticoagulant; (c) then mixing it with a coagulation initiator; (d) spreading the mixture onto a support matrix at a separate location; (e) allowing it to clot on the support matrix to form the dressing; and (f) applying the dressing to the wound for at least two days Compl. ¶33
• Independent Claim 9 recites a method nearly identical to Claim 1, but is specifically directed to treating a "chronic ulcer" Compl. ¶33
• The complaint also asserts dependent claims 4, 5, 6, 7, and 8 and reserves the right to assert others Compl. ¶61

III. The Accused Instrumentality

Product Identification

The accused instrumentality is the FastSkin® Patch, described as a "convenience kit" for producing a wound dressing from a patient's own blood Compl. ¶1 Compl. ¶34

Functionality and Market Context

• The complaint alleges, based on Defendant's 510(k) submission, that the FastSkin® Patch is a kit used at the point of care for the "safe and rapid preparation of Whole Blood Clot (WBC) from a small sample of a patient's own peripheral blood" Compl. ¶36
• The alleged process involves: (1) drawing 20 mL of blood into sterile tubes containing an ACD-A anticoagulant; (2) mixing a calcium gluconate and kaolin powder suspension with the anticoagulated blood; (3) adding the mixture to a "sterile coagulation cartridge" to coagulate for 8 minutes; and (4) transferring the resulting clot to a non-adherent dressing, which is then applied to the wound Compl. ¶37
• The complaint alleges the FastSkin® Patch is intended for the same uses as Plaintiff's ActiGraft® product, including the management of leg ulcers, pressure ulcers, and diabetic ulcers Compl. ¶36 Defendants' identification of ActiGraft® as the predicate device in their FDA submission is cited as an acknowledgement of substantial equivalence Compl. ¶11 Compl. ¶34

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'979 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
withdrawing a volume of whole blood by sterile withdrawal of venous blood from a subject	Withdrawing 20 mL of venous blood from a patient using a sterile blood collection set.	¶39	col. 7:26-28
mixing the volume of whole blood with a coagulation initiator	Mixing the whole blood with a coagulation initiator consisting of calcium gluconate and kaolin.	¶39	col. 8:35-38
allowing said whole blood to clot at a location physically separated from the wound to obtain a sterile whole-blood clot	Allowing the whole blood to clot for 8 minutes in a sterile coagulation cartridge, separate from the wound.	¶39	col. 7:9-16
combining said whole-blood clot with a support matrix to form a sterile wound dressing comprising clotted whole blood and the support matrix	Combining the formed clot with a non-adherent dressing, which is alleged to be the support matrix.	¶39	col. 5:25-34
applying said sterile wound dressing onto the wound, and leaving said sterile wound dressing in place for at least two days	Applying the dressing to the wound, with instructions that the procedure may be repeated after a few days, implying it is left in place.	¶39	col. 27:21-23

• Identified Points of Contention:
  • Scope Questions: A central dispute may arise from the differing claim language between Claim 1 and Claim 5 concerning the assembly sequence. Claim 1 requires "combining" the clot with the matrix to form the dressing, which is then applied. Claim 5 requires transferring the clot to the wound and then applying the matrix. The complaint alleges the accused process involves transferring the clot "to a non-adherent dressing and applied to the patient's wound" Compl. ¶37 The case may turn on whether this sequence falls under the scope of Claim 1, Claim 5, or neither.

'142 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
(a) obtaining a volume of sterile whole blood...	Obtaining a volume of sterile whole blood using a sterile blood collection set.	¶41	col. 8:1-3
(b) mixing the volume of sterile whole blood with an anticoagulant, then	Mixing the blood with an ACD-A anticoagulant contained in sterile vacuum tubes.	¶41	col. 4:50-53
(c) mixing the volume of sterile whole blood and anticoagulant with a coagulation initiator, then	Mixing the anticoagulated blood with a coagulation initiator of calcium gluconate and kaolin.	¶41	col. 4:56-62
(d) spreading the volume of sterile whole blood onto a support matrix at a location physically separated from the wound	The complaint alleges this step is met by adding the blood mixture into the "sterile coagulation cartridge," which it equates with the support matrix.	¶41	col. 9:36-44
(e) allowing the volume of sterile whole blood to clot on the support matrix at the physically separated location...	The complaint alleges this step is met by allowing the blood to clot within the sterile coagulation cartridge.	¶41	col. 9:36-44
(f) applying the sterile wound dressing... and leaving the sterile wound dressing in place for at least two days	Applying the final dressing to the wound and leaving it in place for at least two days.	¶41	col. 27:4-10

• Identified Points of Contention:
  • Technical Questions: A significant technical question is whether the accused process meets the limitations of claim 1(d) and 1(e). The claim requires spreading liquid blood onto a support matrix and allowing it to clot on the matrix. The complaint describes the accused process as clotting the blood inside a "sterile coagulation cartridge" and then transferring the formed clot to a "non-adherent dressing" Compl. ¶37 This raises the question of whether the "cartridge" can be considered the "support matrix" where clotting occurs, or if there is a fundamental operational mismatch between the claim and the accused method.

V. Key Claim Terms for Construction

Term 1: "support matrix" ('142 Patent)

• Context and Importance: This term is critical for the '142 Patent infringement analysis. Claim 1 requires the blood to be spread onto and clot on the "support matrix." The accused process involves clotting in a "cartridge" and then transferring the clot to a "dressing." Plaintiff's infringement theory appears to depend on construing the "cartridge" as the claimed "support matrix."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent specification describes a support structure functionally, stating it can aid in transfer and contribute to physical properties '142 Patent, col. 5:28-34 The specification also notes a support structure can be "external to the clot" '142 Patent, col. 5:28-29 Plaintiff may argue the cartridge fits this broad functional description.
  • Evidence for a Narrower Interpretation: The specification provides specific examples of a support matrix, such as "a pad of a fibrous material such as gauze" and an "absorbent layer" like "gauze and/or non-woven fabric" '142 Patent, col. 5:35-37 '142 Patent, col. 5:48-52 A defendant may argue that in the accused product, the "non-adherent dressing" is the support matrix, not the "cartridge," and since clotting does not occur on the dressing, the claim is not met.

Term 2: "combining said whole-blood clot with a support matrix" ('979 Patent)

• Context and Importance: The definition of "combining" is central to distinguishing between the methods of independent claims 1 and 5 of the '979 Patent. The sequence of steps in the accused process-forming a clot, placing it on a dressing, and applying the assembly to the wound-must be mapped to the claim language. Whether this constitutes "combining" the clot with the matrix before application (Claim 1) will be a key issue.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not provide a specific definition for "combining," leaving it open to a plain and ordinary meaning. Plaintiff may argue that any act of uniting the clot and matrix to form the final dressing product, such as placing one on the other, falls within this scope.
  • Evidence for a Narrower Interpretation: The patent describes embodiments where a mesh is "embedded" within the clot during its formation '979 Patent, col. 13:10-12 A defendant could argue that "combining" requires a more integral connection than simply placing a finished clot on top of a dressing, and that the accused process does not meet this more stringent interpretation.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, stating that Defendants provide instructions for use with the FastSkin® Patch that direct healthcare professionals to perform the steps of the patented methods (Compl. ¶52; Compl. ¶53). This is allegedly evidenced by marketing materials, such as posters presented at a medical symposium Compl. ¶53 Compl. ¶66
• Willful Infringement: The complaint alleges willful infringement based on Defendants' purported pre-suit knowledge of the patents Compl. ¶58 Compl. ¶71 The allegations are supported by claims that Plaintiff sent notice letters to the CEO of mimiX Biotherapeutics and that Plaintiff's CEO (a named inventor) personally met with and explained the infringement to mimiX executives, who nonetheless indicated an intent to proceed with selling the accused product Compl. ¶¶44-47

VII. Analyst's Conclusion: Key Questions for the Case

1. A Question of Location and Definition: The viability of the infringement claim against the '142 Patent will likely depend on whether the accused product's "sterile coagulation cartridge" can be construed as the claimed "support matrix." The case will require the court to determine if clotting blood within a cartridge and then transferring it to a dressing is functionally and legally equivalent to the claimed method of spreading blood onto a support matrix and allowing it to clot there.
2. A Question of Sequence: For the '979 Patent, a core issue will be the precise sequence of steps. The court must decide if the accused method of forming a clot and then placing it on a dressing before application to a wound aligns with the sequence in Claim 1 ("combining" clot and matrix, then applying) or Claim 5 (applying clot to wound, then applying matrix), or if it represents a distinct, non-infringing process.
3. A Question of Intent: Given the detailed allegations of pre-suit notice, including an in-person explanation of infringement from the inventor, a key question will be whether Defendants' conduct constitutes willful infringement. The evidence of Defendants' alleged knowledge, particularly their own 510(k) submission referencing Plaintiff's product, will be central to determining if enhanced damages are warranted.